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Introduction Results  
• Cancer immunoediting is a process that cancer cells undergo to evade 
the immune system (Figure 1) (Swann & Smyth, 2007). 
• To eliminate nascent tumours, death receptors (DR) 4/5 and Fas 
respond to tumour necrosis factor-related apoptosis-inducing ligand 
and Fas Ligand, respectively, to induce cancer cell apoptosis. 
• To escape immune-mediated killing, cancer cells can reduce the 
expression of death receptors (Shin et al., 2001) and major 
histocompatibility complex (MHC) class I, as well as express co-
inhibitory molecules including programmed death ligand 1 (PD-L1) 
(Escors et al., 2018). 
• Tumour escape is one of the hallmarks of cancer and it is necessary 
for tumour progression (Hanahan & Weinberg, 2011). 
• By targeting these immune markers alone or in combination could 
potentially increase cancer cell death and improve drug efficacy. 
Cell culture  Human cancer cell lines were cultured in DMEM (SW620 
and SW480) or RPMI (MDA-MB-231, MCF-7, PC3 and LNCaP) media 
supplemented with 10% FBS and 1% penicillin-streptomycin. 
 
Cell surface staining Human cancer cell lines (5 x 105) were stained 
with fluorescently labelled anti-human PD-L1, HLA-ABC, DR4/5 and Fas 
antibodies and their matched isotype controls. Cell surface expression 
was assessed using flow cytometry and data was analysed using FlowJo 
software.  
Utilising flow cytometric analysis on breast, prostate and colorectal cancer cell lines, we have 
found differential expression of immune markers depending on the cancer type. These findings 
provide a platform for future work that will entail siRNA knockdown of PD-L1 to determine the 
tumour-intrinsic role of this ligand, in addition to combination therapies including death receptor 
agonists and chemotherapeutic agents in 2D and 3D cell culture.  
Figure 1: The process of  Cancer Immunoediting – Elimination, Equilibrium and Escape.  In the 
elimination phase, immune cells can recognise and eliminate nascent tumours, but some cancer cells avoid 
immune destruction and enter dynamic equilibrium with immune cells. Here, cancer cells develop increased 
genetic instability and undergo immune selection whereby the immune cells select for the cancer cells with the 
ability to evade the immune systems defences leading to immune escape and tumour progression.  
Figure 3: Breast, prostate and colorectal cancer cell lines express differential levels of cell surface MHC class I. A) Representative 
flow cytometry plots are shown for each human cancer cell line. They show the difference between the isotype control (grey) and the MHC 
class I (HLA-ABC) positive population. B) Breast (MDA-MB-231 and MCF-7), prostate (LNCaP and PC3) and colorectal (SW620 and 
SW480) cancer cell lines express moderate to high levels of MHC class I. Data is presented as mean ± SD, n=3. 
Figure 4: Breast, prostate and colorectal cancer cell lines express differential levels of cell surface DR4 and DR5. Representative 
flow cytometry plots are shown for each human cancer cell line. They show the difference between the isotype control (grey) and the DR4 
(A) and DR5 (B) positive population. (C) Breast (MDA-MB-231 and MCF-7), prostate (LNCaP and PC3) and colorectal (SW620 andSW480) 
cancer cell lines have low to moderate expression of DR4. D) Breast (MDA-MB-231), prostate (LNCaP and PC3) and colorectal (SW620 
and SW480) cancer cell lines express high levels of DR5, only MCF-7 displayed moderate expression of DR5. Data is presented as mean ± 
SD, n=2. 
• This research aimed to determine the cell surface expression of 
immune markers including PD-L1, MHC class I, DR 4/5 and Fas in 
diverse human cancer cell lines. 
• It was hypothesised that human breast, prostate and colorectal cancer 
cell lines would express PD-L1, MHC class I, DR 4/5 and Fas. 
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Figure 2: Breast, prostate and colorectal cancer cell lines express differential levels of cell surface  
PD-L1. A) Representative flow cytometry plots are shown for each human cancer cell line. They show the 
difference between the isotype control (grey) and the PD-L1 positive population. B) Breast cancer cell line 
MDA-MB-231 express high levels of PD-L1. Breast (MCF-7), prostate (LNCaP and PC3) and colorectal 
(SW620 and SW480) cancer cell lines express low levels of PD-L1. Data is presented as mean ± SD, n=3. 
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Figure 5: Breast, prostate and colorectal cancer cell lines express differential levels of cell surface Fas. A) Representative flow 
cytometry plots are shown for each human cancer cell line. They show the difference between the isotype control (grey) and the Fas positive 
population. B) Breast (MDA-MB-231 and MCF-7) and colorectal (SW620 and SW480) cancer cell lines express low levels of Fas whereas 
prostate (LNCaP and PC3) cancer cell lines express moderate to high levels of Fas. Data is presented as mean ± SD, n=2. 
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